← Oncology Approval Tracker

FDA DECISION ·

Frindovyx

cyclophosphamide · Avyxa Holdings

FDA approvalNew formulationMultiple cancer types
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An IV cyclophosphamide presentation for labeled malignancies including selected lymphomas, leukemias, multiple myeloma, mycosis fungoides, neuroblastoma and specified solid tumors.

LAMPGEN ANALYSIS

Why it matters

This separate NDA adds an IV presentation of an established alkylating drug.

What research teams should watch

Record the exact presentation used in the protocol and match preparation to the product-specific label.

PRIMARY RECORDS

Sources